Citadel Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History
Bought
Maintained
Sold
Other funds holding FBT
Citadel Advisors's FBT Position: Q3 2026 in Review
Citadel Advisors increased its First Trust NYSE Arca Biotechnology Index Fund (FBT) stake by 389% in Q3 2026, buying an estimated $5.42M and bringing the position to 26,224 shares worth $7.14M. The position accounts for ﹤0.01% of the portfolio, ranked #4220.
Citadel Advisors first reported a position in FBT in Q4 2014 and has held it in 42 quarters since. The position peaked at $9.4M in Q3 2015. 350 funds tracked by Wall St. Rank hold FBT as of Q3 2026.
- Citadel Advisors held 26,224 shares of First Trust NYSE Arca Biotechnology Index Fund worth $7.14M as of Q3 2026.
- Citadel Advisors bought 20,860 First Trust NYSE Arca Biotechnology Index Fund shares in Q3 2026, an estimated $5.42M.
- First Trust NYSE Arca Biotechnology Index Fund made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #4220 holding.
- Citadel Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2014 and has held it in 42 quarters since.
- Citadel Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $9.4M in Q3 2015.
- 350 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.